TABLE 2.
Baseline characteristics of patients by atorvastatin subgroup
| 10 mg |
20 mg |
40 mg |
80 mg |
|||||
| Variable | T/A N = 3,218 | AN = 3,274 | T/A N = 2,036 | AN = 2,027 | T/A N = 1,508 | AN = 1,559 | T/A N = 771 | AN = 674 |
| Male sex, no. (%) | 2,489/3,218 (77.3) | 2,564/3,274 (78.3) | 1,579/2036 (77.6) | 1,551/2,027 (76.5) | 1,174/1,508 (77.9) | 1,212/1, 559 (77.7) | 612/771 (79.4) | 534/674 (79.2) |
| White race, no. (%) | 2,975/3,217 (92.5) | 3,036/3,274 (92.7) | 1,888/2,036 (92.7) | 1,901/2,027 (93.8) | 1,433/1,508 (95.0) | 1,469/1, 559 (94.2) | 723/771 (93.8) | 622/674 (92.3) |
| Age (yrs) | 62.0 ± 7.6 | 62.0 ± 7.5 | 61.3 ± 7.5 | 61.1 ± 7.6 | 60.6 ± 7.6 | 60.4 ± 7.6 | 59.8 ± 7.6 | 60.4 ± 7.5 |
| Weight (kg) | 89.3 ± 17.9 | 89.1 ± 17.7 | 90.3 ± 18.7 | 90.8 ± 18.2 | 89.3 ± 17.7 | 90.1 ± 17.2 | 89.8 ± 17.9 | 89.6 ± 17.7 |
| BMI (kg/m) | 30.1 ± 5.7 | 30.0 ± 5.6 | 30.4 ± 5.9 | 30.6 ± 5.9 | 30.0 ± 5.6 | 30.2 ± 5.4 | 30.2 ± 5.5 | 30.1 ± 5.2 |
| Smoking history, no. (%) | ||||||||
| Current smoker | 406/3,218 (12.6) | 409/3,274 (12.5) | 275/2,036 (13.5) | 308/2,027 (15.2) | 214/1,508 (14.2) | 230/1,559 (14.8) | 116/771 (15.0) | 100/674 (14.8) |
| Former smoker | 1,753/3,218 (54.5) | 1,779/3,274 (54.3) | 1,142/2,036 (56.1) | 1,088/2,027 (53.7) | 855/1,508 (56.7) | 859/1,559 (55.1) | 417/771 (54.1) | 397/674 (58.9) |
| Nonsmoker | 1,059/3,218 (32.9) | 1,086/3,274 (33.2) | 619/2,036 (30.4) | 631/2,027 (31.1) | 439/1,508 (29.1) | 470/1,559 (30.1) | 238/771 (30.9) | 177/674 (26.3) |
| Medical History, no./total no. (%) | ||||||||
| Hypertension | 2,254/3,204 (70.3) | 2,403/3,267 (73.6) | 1,499/2,029 (73.9) | 1,511/2,022 (74.7) | 1,087/1,503 (72.3) | 1,138/1,553 (73.3) | 583/768 (75.9) | 502/673 (74.6) |
| Coronary revascularization | 2,051/3,218 (63.7) | 2,076/3,274 (63.4) | 1,355/2,036 (66.6) | 1,320/2,027 (65.1) | 1,151/1,508 (76.3) | 1,186/1,559 (76.1) | 631/771 (81.8) | 551/674 (81.8) |
| MyocardialiInfarction | 1,432/3,194 (44.8) | 1,432/3,252 (44.0) | 870/2,020 (43.1) | 853/2,007 (42.5) | 724/1,491 (48.6) | 741/1,545 (48.0) | 424/758 (55.9) | 362/668 (54.2) |
| Angina | 1,852/3,200 (57.9) | 1,814/3,261 (55.6) | 1,191/2,026 (58.8) | 1,194/2,016 (59.2) | 1,009/1,507 (67.0) | 1,025/1,554 (66.0) | 529/766 (69.1) | 464/668 (69.5) |
| Diabetes | 1,496/3,212 (46.6) | 1,583/3,259 (48.6) | 913/2,032 (44.9) | 971/2,020 (48.1) | 588/1,504 (39.1) | 598/1,554 (38.5) | 274/769 (35.6) | 238/671 (35.5) |
| Peripheral vascular disease | 351/3,176 (11.1) | 350/3,222 (10.9) | 263/2,008 (13.1) | 251/1,998 (12.6) | 202/1,484 (13.6) | 224/1,530 (14.6) | 114/758 (15.0) | 119/667 (17.8) |
| Congestive heart failure (class I or II) | 203/3,207 (6.3) | 220/3,257 (6.8) | 137/2,024 (6.8) | 145/2,016 (7.2) | 100/1,498 (6.7) | 101/1,547 (6.5) | 64/765 (8.4) | 57/669 (8.5) |
| Stroke | 175/3,212 (5.4) | 191/3,269 (5.8) | 109/2,032 (5.4) | 104/2,019 (5.2) | 77/1,501 (5.1) | 79/1,553 (5.1) | 33/767 (4.3) | 37/672 (5.5) |
| Transient ischemic attack | 126/3,200 (3.9) | 161/3,250 (5.0) | 80/2,027 (3.9) | 129/2,009 (6.4) | 66/1,499 (4.4) | 78/1,547 (5.0) | 39/764 (5.1) | 37/671 (5.5) |
| Lipids | ||||||||
| Cholesterol, mg/dl | ||||||||
| Total | 155.4 ± 25.6 | 156.0 ± 26.0 | 157.7 ± 26.4 | 158.9 ± 26.7 | 158.3 ± 26.9 | 157.4 ± 27.8 | 157.3 ± 30.1 | 158.2 ± 29.6 |
| HDL | 48.8 ± 12.5 | 48.7 ± 12.7 | 48.5 ± 11.9 | 48.4 ± 11.8 | 48.9 ± 11.8 | 48.4 ± 12.1 | 47.2 ± 10.6 | 47.9 ± 11.5 |
| LDL | 78.5 ± 20.3 | 78.7 ± 20.2 | 80.0 ± 20.2 | 80.5 ± 21.1 | 80.1 ± 21.0 | 79.7 ± 21.4 | 80.9 ± 22.7 | 81.5 ± 22.3 |
| Triglyceride, mg/dl | ||||||||
| Median | 123.0 | 125.0 | 132.0 | 130.0 | 131.0 | 129.0 | 129.5 | |
| Interquartile range | 90.0, 174.0 | 91.0, 178.0 | 94.0, 181.0 | 95.0, 185.0 | 94.0, 179.0 | 94.0, 175.0 | 94.0, 182.0 | 97.0, 178.0 |
| ApoA-I | 129.3 ± 23.7 | 129.2 ± 23.6 | 128.6 ± 23.3 | 128.4 ± 22.9 | 127.7 ± 22.8 | 127.3 ± 22.9 | 123.1 ± 21.4 | 125.7 ± 22.8 |
| ApoB | 71.7 ± 15.2 | 72.0 ± 15.2 | 74.3 ± 15.6 | 74.7 ± 15.7 | 74.2 ± 16.2 | 74.2 ± 16.5 | 74.2 ± 17.3 | 75.0 ± 17.1 |
| Vital signs | ||||||||
| BP, mm Hg | ||||||||
| Systolic | 123.2 ± 11.0 | 123.6 ± 10.8 | 123.0 ± 10.9 | 123.0 ± 10.9 | 122.8 ± 10.6 | 122.4 ± 11.0 | 121.7 ± 11.0 | 121.5 ± 11.2 |
| Diastolic | 73.8 ± 7.6 | 74.0 ± 7.4 | 73.6 ± 7.6 | 74.0 ± 7.6 | 74.1 ± 7.6 | 73.9 ± 7.4 | 73.1 ± 7.7 | 72.6 ± 7.9 |
| Heart rate, beats/min | 65.5 ± 9.9 | 65.4 ± 9.7 | 65.5 ± 9.4 | 65.5 ± 9.5 | 65.2 ± 9.4 | 65.4 ± 9.3 | 64.8 ± 8.9 | 65.2 ± 9.1 |
| Electrolytes, mmol/l | ||||||||
| Potassium | 4.4 ± 0.4 | 4.4 ± 0.4 | 4.4 ± 0.4 | 4.4 ± 0.4 | 4.4 ± 0.4 | 4.4 ± 0.4 | 4.4 ± 0.4 | 4.4 ± 0.4 |
| Sodium | 140.4 ± 2.8 | 140.3 ± 2.7 | 140.3 ± 2.7 | 140.4 ± 2.8 | 140.4 ± 2.6 | 140.4 ± 2.8 | 140.5 ± 2.8 | 140.6 ± 2.7 |
| Chloride | 102.7 ± 2.9 | 102.6 ± 2.9 | 102.8 ± 2.9 | 102.7 ± 2.9 | 102.7 ± 2.9 | 102.9 ± 2.9 | 103.1 ± 2.9 | 103.1 ± 3.0 |
| Bicarbonate | 24.3 ± 3.1 | 24.4 ± 3.2 | 24.2 ± 3.0 | 24.3 ± 3.0 | 24.5 ± 2.9 | 24.3 ± 3.0 | 24.3 ± 2.8 | 24.3 ± 2.9 |
| Renal function | ||||||||
| Creatinine, mg/dl | 1.00 ± 0.22 | 1.00 ± 0.22 | 1.01 ± 0.22 | 1.00 ± 0.21 | 1.00 ± 0.21 | 1.01 ± 0.22 | 1.01 ± 0.22 | 1.01 ± 0.21 |
| Estimated glomerular filtration rate, ml/min/1.73m | 85.5 ± 22.2 | 85.3 ± 21.3 | 84.8 ± 20.8 | 85.4 ± 20.7 | 86.0 ± 21.7 | 85.1 ± 20.7 | 85.3 ± 20.6 | 84.7 ± 20.4 |
| Other selected measures | ||||||||
| CRP, mg/l | ||||||||
| Median | 1.4 | 1.5 | 1.3 | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 |
| Interquartile range | 0.7, 3.1 | 0.8, 3.3 | 0.6, 2.8 | 0.7, 2.9 | 0.6, 2.5 | 0.6, 2.8 | 0.6, 2.5 | 0.6, 2.5 |
Baseline clinical characteristics were determined following a run-in period of 4 to 10 weeks during which patients underwent lifestyle counseling and also received atorvastatin, titrated if needed, at 2 week intervals to achieve an LDL-C of less than 100 mg per deciliter. Plus-minus values indicate means ± SD. Percentages are based on nonmissing values in that randomized treatment group. Median triglycerides and CRP presented instead of mean due to skew of the data.